Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: tom r. phillips who wrote (160)	6/23/1998 5:28:00 PM
From: tom r. phillips	Read Replies (1) \| Respond to of 668

Emory University/Sofamor Danek/LMP-1 gene i spoke to Karla MacDonald of CBMI IR re. the article described in the previous post. (also faxed her a copy -- she said she'd call back and comment.) i was impressed by her apparent familiarity with CBMI technology. she noted that there are a number of bone morphogenic proteins being developed by various groups. CBMI's OP-1 has a one-year lead to market over what CBMI regards as its closest competitor, Genetics Institute. tom phillips